Predictive biomarkers are revamping drug development and breathing new life into old and failed drugs. But this re-thinking of what works, in who, and why raises questions about cost and accessibility. Precision may be pricy.
When Alexander Graham Bell phoned it in, so to speak, who could have predicted that it would eventually lead to IBM’s Watson Health tackling medication adherence with state-of-the-art analytics?
Information overload from a flood of new diagnostics forces insurers to ramp up prior authorization and utilization review.
Manufacturers are starting to offer significant rebates in exchange for preferred status on an insurer’s formulary.
California and other states have put monthly caps on out-of-pocket medication expenses. But the caps might shift some costs over to premiums.
A Harvard Law School group is among those that have taken action.
Managed care organizations need to work on several fronts if they are to improve patient adherence. Limiting out-of-pocket costs is one place to start.
Sarepta’s eteplirsen functions like an RNA patch so functioning dystrophin gets made. Other drugs like it may be used to treat Ebola and other viral infections.